Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
The Benefits of I-Bonds
Barbara A. Friedberg, CEO at Wealth Media joined Cheddar News to discuss I-bonds, which are issued by the government, and how yields are adjusted.
Inflation Showing Signs of Easing
Greg McBride, chief financial analyst at Bankrate.com, joined Cheddar News to discuss inflation trends. “I think with strong confidence that peak inflation is behind us, the trend is definitely one towards continued improvement but we've got a long way to go,” he said.
Load More